Nightingale Health - New Blood on the Stock Market

Although I was a long-time NGH believer, I have been shouting here about Tuukka Paavola’s suspicious, hasty departure from the CFO position as a red flag. The CEO’s icy “thanks… [expletive] for absolutely nothing” words didn’t ease my fears one bit.

On the contrary.

My worst-case scenario then was that Paavola would have had to do something so unethical within his role that he refused and chose to walk out, slamming the door instead.

After mulling over that news for a long time, and with sales stalling (either Terveystalo or Moli-Sani or something else is lagging or stuck for some reason), and the share price sliding below 1.5 euros, I dumped 30% of my holdings at a loss.

Only today (I’m sometimes slow, sometimes stupid, and often both) did it become clear to me, thanks to @Vino_Pino in the BRETEC thread, that Paavola has apparently been the CFO of that outfit for TWO MONTHS already.

And as CFO, he is responsible for the ongoing and potentially future printing of 1.75 billion shares, which is going to take an incomprehensibly outrageous amount of ink.

Paavola’s dramatic exit may, in the end, be a really good signal for NGH owners.

Our Silver Lining.

Today I bought back a small piece of my big panic sell—at the day’s peak price, of course.

This stock is so tightly wound right now that it can’t even handle a lukewarm-neutral-positive LINKEDIN (seriously!) update without jumping a quick 10%.

I’m still waiting for buying opportunities under 1 euro if announcements about concrete sales increases (or large contracts that take a long time to monetize) don’t start trickling in.

And quite soon.

4 Likes